Edgar Filing: Genmed Holding Corp

f10q210_form-genm.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2010

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

EXCHANGE ACT

Commission File Number: 000-26607

GENMED HOLDING CORP.

[Missing Graphic Reference]

Exact name of registrant as specified in its charter

NEVADA	88-0390828
(State or other jurisdiction of	I.R.S. Employer
incorporation or organization)	Identification No.

Rontgenlaan 27, 2719 DX

Zoetermeer, The Netherlands

[Missing Graphic Reference]

(Address of principal executive offices)

011-31-793-630-129

[Missing Graphic Reference]

Registrant's telephone number, including area code

N/A

___________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days Yesx No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer o

Non-accelerated filer o (Do not check if a smaller reporting company) Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes x No o

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. Yes o No o

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 162,777,533 shares of common stock as of August 23, 2010.

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

GENMED HOLDING CORP.

FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2010 AND 2009

CONTENTS

______________________________________________________________________________________

Consolidated Balance Sheets as of June 30, 2010 (Unaudited) and December 31, 2009

Page 4

Consolidated Statements of Operations for the three months and six months ended June 30, 2010 and 2009 (Unaudited)

Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and 2009 (Unaudited)

Notes to Consolidated Financial Statements (Unaudited)

GENMED HOLDING CORP. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	June 30,				December 31,
	2010				2009
	(Unaudited)
ASSETS

CURRENT ASSETS
Cash		$	20,418		$	-
Accounts receivable			18,951			81,864
VAT receivable			3,494			6,454
Total Current Assets			42,863			88,318

EQUIPMENT, net accumulated depreciation of $6,522 and $5,832			9,163			12,587

MEDICAL REGISTRATION RIGHTS, net accumulated amortization
of $2,558,668 and $2,197,061			5,788,393			6,150,000

Total Assets		$	5,840,419		$	6,250,905

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Bank overdraft		$	-		$	493
Accounts payable			289,387			266,680
Accrued salaries and related expenses			341,736			357,539
Accrued expenses			843,464			513,880
Convertible debentures			-			1,146,557
Discount on convertible debentures			-			(342,029	)
Notes payable			18,308			-
Loans payable to related parties			202,582			204,690
Total Current Liabilities			1,695,477			2,147,810

STOCKHOLDERS' EQUITY
Class A Convertible Preferred Stock, par value $0.001; authorized
500,000,000 shares; there were no shares issued and outstanding at
June 30, 2010 and December 31, 2009, respectively.			-			-
Common stock, par value $0.001; authorized 500,000,000 shares;
issued and outstanding- 153,577,533 and 123,211,739 shares at
June 30, 2010 and December 31, 2009, respectively			153,576			123,212
Additional paid-in capital			67,429,182			66,240,744
Accumulated deficit			(63,531,451	)		(62,266,626	)
Accumulated other comprehensive income			93,635			5,765
Total Stockholders' Equity			4,144,942			4,103,095

Total Liabilities and Stockholders' Equity		$	5,840,419		$	6,250,905



See accompanying notes to consolidated financial statements

GENMED HOLDING CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)


	For theThree Months Ended						For the Six Months Ended
	June 30,						June 30,
	2010			2009			2010			2009

NET SALES	$	503		$	49,775		$	503		$	49,775

COST AND EXPENSES:
Selling, general and administrative		204,516			165,458			470,523			479,816
Depreciation and amortization		181,700			364,873			363,460			725,702
Research & development		14,155			7,826			43,211			40,687
Total Costs and Expenses		400,371			538,157			877,194			1,246,205

NET OPERATING LOSS		(399,868	)		(488,382	)		(876,691	)		(1,196,430	)

OTHER INCOME (EXPENSE)
Gain on cancellation of consulting agreement		-			285,000			-			285,000
Loss on foreign exchange		(22,069	)		(5,806	)		(42,294	)		(12,227	)
Interest expense		(4,243	)		(16,495	)		(345,840	)		(33,177	)
Total Other Income (Expense)		(26,312	)		262,699			(388,134	)		239,596

NET LOSS	$	(426,180	)	$	(225,683	)	$	(1,264,825	)	$	(956,834	)

OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation		52,944			(20,232	)		87,870			(17,694	)

COMPREHENSIVE LOSS	$	(373,236	)	$	(245,915	)	$	(1,176,955	)	$	(974,528	)

NET LOSS PER COMMON SHARE
(BASIC AND DILUTED)	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)

WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING		153,328,320			123,478,406			143,095,113			124,545,072



See accompanying notes to consolidated financial statements

GENMED HOLDING CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)


	For the six months ended
	June 30,
	2010			2009
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(1,264,825	)	$	(956,834	)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization		363,460			725,702
Amortization of beneficial conversion feature		342,029
Stock based compensation		-			102,000
Changes in operating assets and liabilities:
Accounts receivable		62,913			(28,097	)
VAT receivable		2,960			6,231
Accounts payable		22,707			21,637
Accrued salaries and related expenses		(15,803	)		21,967
Accrued expenses		380,979			(188,797	)
Net Cash Used in Operating Activities		(105,580	)		(296,191	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of equipment		-			-
Net Cash Used in Investing Activities		-			-

CASH FLOWS FROM FINANCING ACTIVITIES
Bank overdraft		(493	)		-
Proceeds from notes payable		18,308			-
Proceeds from sale of common stock		20,850
Advances from notes payable to related parties		-			314,458
Repayment of notes payable to related parties		(2,108	)		-
Net Cash Provided by Investing Activities		36,557			314,458

EFFECT OF EXCHANGE RATE		89,441			(17,551	)

INCREASE (DECREASE) IN CASH		20,418			716

CASH, BEGINNING OF PERIOD		-			1,764
CASH, END OF PERIOD	$	20,418		$	2,480

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Non cash activities:
Conversion of convertible debentures into common stock	$	1,197,952			-
Conversion of related party debt to convertible debenture		-		$	925,000
Beneficial conversion feature on convertible debenture		-			462,500
Cancellation of common stock		-			2,400


See accompanying notes to consolidated financial statements

GENMED HOLDING CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2010

NOTE 1 – BASIS OF PRESENTATION

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary in order to make the financial statements not misleading have been included. Results for the three and six ended June 30, 2010 are not necessarily indicative of the results that may be expected for the year ending December 31, 2010. For further information, refer to the financial statements and footnotes thereto included in the Genmed Holding Corp. and Subsidiaries annual report on Form 10-K for the year ended December 31, 2009.

NOTE 2 – GOING CONCERN

As shown in the accompanying financial statements, the Company has incurred an accumulated deficit of $63,531,451 and has negative working capital of $1,652,614. Management's plans include the raising of capital through the equity markets to fund future operations and the generating of revenue through its business. Failure to raise adequate capital and generate adequate sales revenues could result in the Company having to curtail or cease operations. Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues, there can be no assurance that the revenue will be sufficient to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company's ability to continue as a going concern. However, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3 – GENERAL RELEASE AND SETTLEMENT AGREEMENT

On April 17, 2008, the Company entered into a General Release and Settlement Agreement (the "General Release Agreement") with Total Look, B.V. (“Total Look”), London Finance Group, Ltd., a California corporation (“LFG”), Dojo Enterprises, LLC, a Nevada limited liability company (“Dojo”), Hyperion Fund, L.P., a Colorado limited partnership (“Hyperion”), The Palisades Capital, LLC 401(k) Profit Sharing Trust (“Palisades”), The Morpheus 2005 Trust dated December 1, 2005 (“Morpheus”), Burton Partners, LLC (“Burton”), Picasso, LLC (“Picasso”) and Glacier, LLC (“Glacier,” and, together with Total Look, LFG, Dojo, Hyperion, Palisades, Morpheus, Burton and Picasso, the “Preferred Shareholders”) to settle all accounts and disputes between the parties and to avoid the expense and delay of litigation.

Pursuant to the General Release Agreement, the Company issued 39,000,000 warrants to the Preferred Shareholders, which were subsequently cancelled, to purchase shares of common stock of the Company.

The Preferred Shareholders collectively own 2,179,533 shares of Class A Convertible Preferred Stock of the Company, which equals 100% of the outstanding preferred shares of stock of the Company. Pursuant to the General Release Agreement, all of the outstanding preferred shares of the Company were cancelled upon the issue of the common stock to the Preferred Shareholders.

Subsequent to December 31, 2008, on or around April 11, 2009, the Preferred Shareholders entered into a Release and Settlement Agreement in which the parties agreed to the cancellation of all the warrants and to the cancellation and re-issuing of certain shares of Common Stock that were issued pursuant to the General Release and Settlement Agreement of April 17, 2008.

GENMED HOLDING CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2010

NOTE 3 – GENERAL RELEASE AND SETTLEMENT AGREEMENT (Continued)

Pursuant to the Release and Settlement Agreement of April 11, 2009, such shares of common stock of the Company are now issued as follows:

Shareholder	Common Stock
Total Look B.V.	62,678,826 shares
Dojo Enterprises, Ltd.	1,120,107 shares
Hyperion Fund, L.P.	1,760,428 shares
Diane Breitman, as Trustee of The Morpheus 2005 Trust	2,720,000 shares
Burton Partners, LLC	2,240,213 shares
Picasso, LLC	2,240,213 shares
Glacier, LLC	2,240,213 shares

TOTAL	75,000,000 shares

NOTE 4- STOCK EXCHANGE AGREEMENT

On April 17, 2008, Genmed Holding Corp. ("Genmed," or the “Company”) entered into a Stock Exchange Agreement (the "Stock Exchange Agreement") with Joost de Metz (“de Metz”), Willem Blijleven (“Blijleven”), Erwin R. Bouwens (“Bouwens”) and Medical Network Holding BV (“MNH,” and collectively with de Metz, Blijlevens and Bouwens, the “Shareholders”). The Shareholders were holders of 100% of the outstanding capital stock of Genmed BV (“GMBV”), a company organized in The Netherlands.

Pursuant to the Stock Exchange Agreement, Genmed agreed to purchase from the Shareholders 18,000 restricted shares of the registered and outstanding capital stock of GMBV (the “GMBV Shares”), representing 100% of its outstanding capital stock, for a purchase price equal to 48,000,000 shares of restricted common stock of Genmed and the issuance of 24,000,000 warrants at $0.10 per share.

Subsequent to December 31, 2008, on or around April 11, 2009, the ‘Shareholders’ entered into a Release and Settlement Agreement in which the parties agreed to the cancellation of all the warrants that were issued pursuant to the Stock Exchange Agreement of April 17, 2008.

The fair value of the assets acquired is as follows:

Cash	$	4,993
Receivables		17,513
Fair Value of Medical Registration Rights		14,600,000
Liabilities Assumed		(6,153	)
		14,616,353
Fair value of 48,000,000 shares @ $0.51 per share and 24,000,000 warrants valued at 9,881,923		34,361,923
Impairment of Goodwill	$	19,745,570

The Medical Registration Rights represent a distribution agreement with Atabay Group to distribute generic drugs in various European Union and other countries outside the European Union as well as the registration rights to Paracetamol (acetaminophen), a generic form of Tylenol, in the European Union. These rights are being amortized over their estimated useful life of 10 years. Amortization expenses for the year ended December 31, 2009 was $1,460,000. Estimated future amortization for the next five years is as follows:

2010	$	745,000
2011		745,000
2012		745,000
2013		745,000
2014		745,000

GENMED HOLDING CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2010

NOTE 4 – STOCK EXCHANGE AGREEMENT (Continued)

Subsequent to the acquisition of Genmed BV, the Company tested the business unit for impairment. As a result, the Company determined that the Goodwill was impaired and wrote off the entire balance of $19,745,570.

NOTE 5- IMPAIRMENT OF MEDICAL REGISTRATION RIGHTS

The Company reviewed its medical registration rights for impairment on December 31, 2009. The Company determined that its’ inability to obtain authorization to market drugs under the Atabay agreement, its’ inability to generate the revenues originally anticipated, and the difficulty in raising the funds to market the rights indicated that the carrying amount of the medical registration rights may not be recoverable. The Company valued the medical registration rights on December 31, 2009 using the income approach. In valuing the medical registration rights, the Company considered the projected sales for Paracetamol in the approved markets in the European Union. The Company determined that the value of the medical registration rights on December 31, 2009 was $6,150,000. As such, an impairment loss of $6,252,359 was recognized.

NOTE 6- CONSULTING AGREEMENTS

Subsequent to December 31, 2008, on or around April 11, 2009, the Company and London Finance Group entered into a Release and Settlement Agreement in which the parties agreed to rescind the Consultancy Agreement entered into by the Company and the London Finance Group on April 17, 2008 and to cancel the shares and warrants that have been issued pursuant to the Consulting Agreement as well as to waive all monies owed by the Company to the London Finance Group as part of the same Consulting Agreement. As part of this agreement, the Company recognized $285,000 as a Gain on the cancellation of the amounts due under the consulting agreements.

NOTE 7 – NOTES PAYABLE TO RELATED PARTIES

On June 30, 2009, the Company and two note holders agreed upon the consolidation of their notes, including the unpaid interest, and to issue a new 100% Premium Secured Convertible Promissory Note. The new note is issued for the amount of $925,000, bears an annual interest rate of 8% and is convertible into shares of the Company’s Common Stock at a share price of $0.04 per share. The Secured Promissory Note is due on June 30, 2010. A beneficial conversion feature of $462,500 was recognized as part of this conversion and is being amortized over the year of the Secured Promissory Note. As such, the beneficial conversion feature of $462,500 is included as a discount to the convertible debenture at June 30, 2009.

On December 31, 2009, the Company and Mr. Bouwens, the CEO of the Company, agreed upon the conversion of his note, including the unpaid interest, and to issue a new 100% Premium Secured Convertible Promissory Note. The new note is issued for the amount of $221,557, bears an annual interest rate of 8% and is convertible into shares of the Company’s Common Stock at a share price of $0.04 per share. The Secured Promissory Note is due on December 31, 2010. A beneficial conversion feature of $110,779 was recognized as part of this conversion and is being amortized over the year of the Secured Promissory Note.

On March 3, 2010, the holders of the Convertible notes have converted their notes including the unpaid interest into shares of the Company’s Common Stock. As such, the Company has issued 29,948,794 of new shares of Common Stock of the Company.

Besides the funds that The Company has received from the convertible note holders, the Company has received other advances from individuals related to the Company at various times for working capital and to fund required operating expenses. These advances are unsecured and bear interest at the rate of 8% per year. The amount outstanding at June 30, 2010 and December 31, 2009 aggregate $202,582 and $204,690 respectively.

NOTE 9 – NOTES PAYABLE

In June 2010, as part of the implementation of its business plan, the Company issued €15,000 ($18,308) in bonds. The bonds have a term of 48 months and bearing an annual interest rate of 7.4%.

GENMED HOLDING CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

JUNE 30, 2010

NOTE 9 – NOTES PAYABLE (CONTINUED)

The Bonds are recallable, after 10, 22 or 34 months, with a notice of two months and with a penalty of 10% of the value of the bond, up to a yearly maximum of 5% of the total funds received through the issuances of such bonds. Buyback requests will be handled in order of entries

NOTE 10 – STOCK ISSUANCES

On May 19, 2010, in exchange for $14,880 (€12,000) in cash, the Company issued 297,600 shares of its common stock at $0.05 per share to a non-related individual.

On June 8, 2010, in exchange for $5,970 (€5,000) in cash, the Company issued 119,400 shares of its common stock at $0.05 per share to a non-related individual.

NOTE 11 – LITIGATION

The Company has been named as a defendant in a lawsuit filed in the Circuit Court of the 11th Judicial Circuit in Miami-Dade County, Florida, Case No. 08-79227CA25. The Company’s former Chief Executive Officer, Jerri Palmer, has instigated the lawsuit against the Company alleging Breach of Contract and Unjust Enrichment. Ms. Palmer is claiming damages in excess of $15,000. Ms. Palmer was the Company’s Chief Executive Officer from December 5, 2005, until her resignation on May 19, 2006. The Company has alleged counter claims against Ms. Palmer for breach of contract and breach of fiduciary duty.

In March 2010, the Company and Ms. Palmer settled the lawsuit for an amount of $40,000. The Company accrued this settlement in the financial statements at December 31, 2009.

On July 20, 2010, since the Company was not able to pay this amount, Ms. Palmer entered into a final judgment against the Company for $40,000 bearing an annual interest rate at 6%. On July 21, 2010, the Company has paid a first installment of $7,000.

NOTE 12 – SUBSEQUENT EVENT

In July of 2010, as part of the implementation of its business plan, the Company issued a total of 9,200,000 shares of common stock at $0.06 (€0.05) per share to four investors for proceeds of $582,160 (€460,000).

Item 2. Management's Discussion and Analysis of Financial Condition or Results of Operations

Forward-looking Information

This Form 10-Q quarterly report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts, included in this Form 10-Q that address activities, events, or developments that we expect or anticipate will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strength, goals, expansion and growth of our business and operations, plans, references to future success, reference to intentions as to future matters, and other such matters are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. These statements are based up on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments as well as other factors that we believe are appropriate in the circumstances. However, whether actual results and developments will conform to our expectations and predictions is subject to a number of risks, uncertainties, and other factors, many of which are beyond our control.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, we do not assume responsibility for the accuracy and completeness of such forward-looking statements. We are under no duty to update any of the forward-looking statements after the date of this report to conform such statements to actual results.

General

The following discussion and analysis summarizes the results of operations of Genmed Holding Corp. ("Genmed," the "Company," or "we"), formerly called Satellite Newspapers Corp., for the six-month period ended June 30, 2010.

During the six-month period ended June 30, 2010, the Company successfully obtained the sales license for its first generic product within seven countries of the European Union. The Company continued developing its business, and has now entered into negotiations with distributors in three countries within the EU.

The Company has also started negotiations with certain distributors in countries outside the European Union to sell a number of its products. The Company hopes that these negotiations will finally result in sales orders, though the Company anticipates that actual sales will take some time to develop due to the registration requirements in the various countries. The Company believes that the registration process in these countries is less costly and less time consuming than the registration process for countries within the European Union, and hopes to be able to start selling its products in a reasonable time.

On April 17, 2008, the Company entered into a Stock Exchange Agreement (the “Stock Exchange Agreement”) with Genmed BV resulting in Genmed BV becoming a wholly owned subsidiary of the Company. Also on April 17, 2008, the Company entered into a General Release and Settlement Agreement (the “General Release and Settlement Agreement) and a consulting agreement with London Finance Group. See Exhibits 10.1, 10.2, and 10.3 incorporated by reference hereto.

In April 2009, the parties to the Stock Exchange Agreement, the General Release and Settlement Agreement and the consulting agreement described above, agreed and formalized by written agreement, to the cancellation of all of the warrants issued pursuant to such agreements, to the cancellation and re-issuing of certain shares issued pursuant to such agreements, and agreed to the cancellation of the consulting agreement with the London Finance Group, including the cancellation of the shares and warrants that have been issued to the London Finance Group as part of such consulting agreement. See Exhibit 10.4 hereto, Release and Settlement Agreement between the Company, Joost de Metz, Willem Blijleven, E.R. Bouwens Beheermaatschappij B.V., Medical Network Holding BV, Total Look, BV, London Finance Group, Ltd., Dojo Enterprises, LLC, Hyperion Fund, L.P., The Palisades Capital, LLC 401(k) Profit Sharing Trust, The Morpheus 2005 Trust dated December 1, 2005, Burton Partners, LLC, Picasso, LLC, and Glacier, LLC.

Risks

The Company is currently in the development stage of its generic drug distribution business and is attempting to develop and maintain relationships with generic drug manufacturers, retail entities, and government regulatory authorities. If the Company is unable to develop and maintain such relationships or unable to secure and maintain contractual relationships with generic drug manufacturers, retail entities, and government regulatory and licensing authorities the Company may not be able to fulfill its business plan and would likely be unable to continue its operations.

Similarly, if the Company is unable to obtain regulatory licensing to distribute, market, and sell its generic drugs, the Company would likely be unable to continue its operations. The Company is seeking to distribute and sell its generic drugs throughout Europe and in other countries. The Company will be subject to certain regulatory requirements which may cause the Company to incur additional expenses and resources maintaining compliance with such regulations, and may slow or stop the Company’s ability to distribute and sell generic drugs.

The distribution of pharmaceuticals and related healthcare solutions is highly competitive. The Company competes with national wholesale distributors of pharmaceuticals; regional and local distributors of pharmaceuticals; chain drugstores that warehouse their own pharmaceuticals; specialty distributors; and other healthcare providers. As a development stage Company, the Company is competing against more experienced and more developed competitors with greater resources, and established relationships, contracts, and products.

As shown in the accompanying financial statements and notes, the Company has incurred an accumulated deficit of $63,531,451 and has negative working capital of $1,652,614. The Company is reliant upon its officers and directors for capital and intends to raise capital through equity markets to fund future operations and to generate revenue through its business operations. Failure to raise adequate capital and to generate adequate sales revenues could result in the Company being unable to effectuate its business plan. Additionally, even if the Company does raise sufficient capital to support its operating expenses and generate adequate revenues, there can be no assurance that such revenue will be sufficient to enable it to develop business to a level where it will generate profits and cash flow from operations. These matters have raised substantial doubt about the Company's ability to continue as a going concern.

Results of Operations

Comparison of the three months ended June 30, 2010 and 2009

Net Sales. The Company had a minimum of net sales during the three months ended June 30, 2010 compared to $49,775 in net sales for the three months ended June 30, 2009. Such net sales primarily consisted of consulting services and did not include any sales of generic products.

Selling, General, and Administrative expenses. Selling, general, and administrative expenses increased 23,6% to $204,516 during the three month period ended June 30, 2010 as compared to $165,458 for the comparable period in 2009.

Depreciation and Amortization. The Company incurred $181,700 in depreciation and amortization during the three months ended June 30, 2010, compared $364,873 in depreciation and amortization during the three months ended June 30, 2009. The decrease in depreciation and amortization expenses is primarily due to the impairment of the Medical Registration Rights as per December 31, 2009. The Company reviewed its medical registration rights for impairment on December 31, 2009 and determined that the value of the medical registration rights on December 31, 2009 was $6,150,000 and as such, an impairment loss of $6,252,359 was recognized. The depreciation and impairment expenses for the medical registration rights have been adjusted for the new value for the remaining useful life of this asset.

Research and Development. The Company incurred $14,155 in Research and Development expenses during the three months ended June 30, 2010, as compared to $7,826 in Research and Development expenses during the three months ended June 30, 2009.

Net Operating Loss. As a result of the Company’s selling, general, and administrative expenses, the Company incurred a net operating loss of $399,868 for the period ended June 30, 2010, as compared with $488,382 for the period ended June 30, 2009.

Loss on Foreign Exchange and Interest Expense. The Company incurred a loss on foreign exchange during the three month period ended June 30, 2010 of $22,069 compared to a loss of $5,806 for the three month period ended June 30, 2009. The Company incurred interest expenses of $4,243 during the three month period ended June 30, 2010, as compared to $16,495 during the comparable period in 2009. The decrease in interest expense was due primarily to the conversion of the convertible notes. During the first quarter of 2010, the holders of the convertible notes have converted their notes and as such, the Company had no longer to expense interest on these notes during the three month period ending June 30, 2010.

Net Gain (Loss). The Company incurred a net loss of $426,180 during the three month period ended June 30, 2010, as compared with a net loss of $225,683 for the three month period ended June 30, 2009. The increase in net loss was due primarily to the fact that during the three months ended June 2009, as part of the cancellation of the consulting agreement with LFG, we recognized a gain of $285,000, compared to no such gain for the comparable period in 2010.

Comparison of the six months ended June 30, 2010 and 2009

Net Sales. The Company had a minimum of net sales during the period ended June 30, 2010 compared to $49,775 in net sales for the same period ended June 30, 2009. Such net sales primarily consisted of consulting services and did not include any sales of generic products.

Selling, General, and Administrative expenses. Selling, general, and administrative expenses decreased 1,95% to $470,523 during the six month period ended June 30, 2010 as compared to $479,816 for the comparable period in 2009.

Depreciation and Amortization. The Company incurred $363,460 in depreciation and amortization during the six months ended June 30, 2010, compared $725,702 in depreciation and amortization during the six months ended June 30, 2009. The decrease in depreciation and amortization expenses is primarily due to the impairment of the Medical Registration Rights as per December 31, 2009. The Company reviewed its medical registration rights for impairment on December 31, 2009 and determined that the value of the medical registration rights on December 31, 2009 was $6,150,000 and as such, an impairment loss of $6,252,359 was recognized. The depreciation and impairment expenses for the medical registration rights have been adjusted for the new value for the remaining useful life of this asset.

Research and Development. The Company incurred $43,211 in Research and Development expenses during the six months ended June 30, 2010, as compared to $40,687 in Research and Development expenses during the six months ended June 30, 2009.

Net Operating Loss. As a result of the Company’s selling, general, and administrative expenses, the Company incurred a net operating loss of $876,691 for the period ended June 30, 2010, as compared with $1,196,430 for the period ended June 30, 2009.

Loss on Foreign Exchange and Interest Expense. The Company incurred a loss on foreign exchange during the period ended June 30, 2010 of $42,294 compared to a loss of $12,227 for the period ended June 30, 2009. The Company incurred interest expenses of $345,840 during the six month period ended June 30, 2010, as compared to $33,177 during the comparable period in 2009. The increase in interest expense was due primarily to the conversion of the convertible notes. The holders of the convertible notes have converted their notes and as such, the Company had to expense the conversion feature which was recognized as part of this conversion.

Net Gain (Loss). The Company incurred a net loss of $1,264,825 during the period ended June 30, 2010, as compared with a net loss of $956,834 for the period ended June 30, 2009. The increase in net loss was due primarily to the fact that during the three months ended June 2009, as part of the cancellation of the consulting agreement with LFG, we recognized a gain of $285,000, compared to no such gain for the comparable period in 2010.

Liquidity and Capital Resources

At June 30, 2010, the Company had $5,840,419 of total assets. Total assets consisted of $20,418 in cash, $18,951 in accounts receivable, $3,494 in VAT receivables, $15,685 in equipment, $8,347,061 in medical registration rights, and less $2,565,190 of depreciation and amortization.

The Company's working capital deficit was $1,652,614 at June 30, 2010, compared to a working capital deficit of $2,059,492 at December 31, 2009.

At June 30, 2010, the Company had acquired its wholly owned subsidiary Genmed BV, successfully registered its first generic product in seven EU countries and continued developing its business of the distribution and sale of generic drugs. The Company had no revenues in generic products during the six months ended June 30, 2010 and had no revenues in generic products during the six months ended June 30, 2009. The revenues the Company did have in the aforementioned period consisted primarily of consulting services.

As of June 30, 2010, the Company was primarily relying on its corporate officers, directors, and outside investors for the funding needed for the implementation of its business plan. The Company’s management is currently looking for the capital needed to complete its corporate objectives. The Company cannot predict the extent to which its liquidity and capital resources will be available prior to execute its business plan or whether it will have sufficient capital to fund typical operating expenses.

If the Company is unable to obtain financing from any of one of these aforementioned sources, the Company would not be able to complete the financial requirements regarding the development of its generic drug distribution business or to continue as a going concern.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Smaller reporting companies are not required to provide the information required by this item.

Item 4. Controls and Procedures

Disclosure controls and procedures

As of the end of the period covered by this quarterly report, the Company, through its Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to enable us to record, process, summarize and report information required to be included in our reports that we file or submit under the Exchange Act within the time periods required.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) during the quarter ended March 31, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1 Legal Proceedings

The Company was named as a defendant in a lawsuit filed in the Circuit Court of the 11th Judicial Circuit in Miami-Dade County, Florida, Case No. 08-79227CA25 in December 2008. The Company’s former Chief Executive Officer, Jerri Palmer, instigated the lawsuit against the Company alleging Breach of Contract and Unjust Enrichment. Ms. Palmer is claiming damages in excess of $15,000. Ms. Palmer was the Company’s Chief Executive Officer from December 5, 2005, until her resignation on May 19, 2006. The Company believes that Ms. Palmer’s claims are without merit and intends to vigorously defend itself.

In March 2010, the Company and Ms. Palmer have settled the lawsuit for an amount of $40,000. The Company accrued this settlement in the financial statements at December 31, 2009.

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds

On or around April 8, 2009, the parties to the Stock Exchange Agreement, the General Release and Settlement Agreement, and the consulting agreement with London Finance Group, agreed and formalized by written agreement, to the cancellation of all of the warrants issued to such agreements, to the cancellation and re-issuing of certain shares issued pursuant to such agreements, and agreed to the cancellation of the consulting agreement with London Finance Group, including the cancellation of the shares and warrants that were issued to London Finance Group as part of such agreement. See Exhibit 10.4 hereto.

On May 19, 2010, in exchange for $14,880 (€12,000) in cash, the Company issued 297,600 shares of its common stock to a non-related individual.

On June 8, 2010, in exchange for $5,970 (€5,000) in cash, the Company issued 119,400 shares of its common stock to a non-related individual.

Item 3 Defaults Upon Senior Securities

N/A

Item 4 Submission of Matters to a Vote of Security Holders

N/A

Item 5 Other Information

See Part II, Item 2 Unregistered Sales of Equity Securities and Use of Proceeds, above.

Item 6 Exhibits

Exhibit 10.1

Stock Exchange Agreement between the Company and Joost de Metz (“de Metz”), Willem Blijleven (“Blijleven”), Erwin R. Bouwens (“Bouwens”) and Medical Network Holding BV dated April 17, 2008, incorporated herein by reference to Exhibit 9.2 to the Form 8-K current report of the Company filed on May 2, 2008.

Exhibit 10.2

General Release and Settlement Agreement, incorporated herein by reference to Exhibit 9.1 to the Form 8-K current report of the Company filed on May 2, 2008.

Exhibit 10.3

Consulting Agreement between the Company and London Finance Group, Ltd.,

incorporated herein by reference to Exhibit 9.1 to the Form 8-K current report of the Company filed on May 2, 2008.

Exhibit 10.4

Release and Settlement Agreement between the Company, Joost de Metz, Willem Blijleven, E.R. Bouwens Beheermaatschappij B.V., Medical Network Holding BV, Total Look, BV, London Finance Group, Ltd., Dojo Enterprises, LLC, Hyperion Fund, L.P., The Palisades Capital, LLC 401(k) Profit Sharing Trust, The Morpheus 2005 Trust dated December 1, 2005, Burton Partners, LLC, Picasso, LLC and Glacier, LLC, incorporated herein by reference to Exhibit 10.2 to the Form 10-K annual report of the Company filed on May 15, 2009.

Exhibit 31.1

Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 31.2

Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 32

Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 23, 2010	Genmed Holding Corp.


	By: /s/ Randy Hibma
	Randy Hibma, Chief Financial Officer, Vice President, and Secretary